Zoetis ZTS
NYSE ZTS
$75.95 -0.73 (-0.95%)
At close: Aug 20, 2026 · 11:07 AM UTC

Zoetis (ZTS) Cash from Investing Activities (2012 - 2026)

Zoetis (ZTS) posted quarterly Cash from Investing Activities of -$87.0 million for Q1 2026, up 57.14% year-over-year from -$55.4 million in Q1 2025, and up 47.59% quarter-over-quarter from -$166.0 million in Q4 2025.

Zoetis (ZTS) Cash from Investing Activities (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has reported Cash from Investing Activities for 15 consecutive years, with -$87.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Cash from Investing Activities rose 57.14% year-over-year to -$87.0 million; the TTM figure through Mar 2026 stood at -$632.0 million (down 63.31% YoY), while the FY2025 annual figure was -$748.0 million, down 137.46% from the prior year.
  • Cash from Investing Activities climbed to -$87.0 million in Q1 2026 per ZTS's latest filing, from -$166.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $126.0 million in Q4 2024 and bottomed at -$438.0 million in Q4 2022.
  • Historically, Cash from Investing Activities has averaged -$165.3 million across 5 years, with a median of -$166.0 million in 2025.
  • Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 160.0% — and 2025, when it sank 231.75%.
  • Zoetis' Cash from Investing Activities stood at -$438.0 million in 2022, then soared by 52.05% to -$210.0 million in 2023, then jumped by 160.0% to $126.0 million in 2024, then tumbled by 231.75% to -$166.0 million in 2025, then surged by 47.59% to -$87.0 million in 2026.
  • Business Quant data shows ZTS's Cash from Investing Activities at -$87.0 million in Q1 2026, -$166.0 million in Q4 2025, and -$160.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 43.85 Bn 42.88 Bn - -
2 Teva Pharmaceutical Industries 43.31 Bn 39.66 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.65 Bn 29.98 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.68 Bn 22.88 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.18 Bn 19.52 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.82 Bn 17.94 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.70 Bn 15.31 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn - -
10 Alkermes 8.21 Bn 7.55 Bn 397.90 Mn -2.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -300.00 Mn
Jun 30, 2026 -300.00 Mn
Mar 31, 2026 -87.00 Mn
Mar 31, 2026 -87.00 Mn
Dec 31, 2025 -166.00 Mn
Dec 31, 2025 -166.00 Mn
Sep 30, 2025 -160.00 Mn
Sep 30, 2025 -160.00 Mn
Jun 30, 2025 -219.00 Mn
Jun 30, 2025 -219.00 Mn
Mar 31, 2025 -203.00 Mn
Mar 31, 2025 -203.00 Mn
Dec 31, 2024 126.00 Mn
Dec 31, 2024 126.00 Mn
Sep 30, 2024 -178.00 Mn
Sep 30, 2024 -178.00 Mn
Jun 30, 2024 -132.00 Mn
Jun 30, 2024 -132.00 Mn
Mar 31, 2024 -131.00 Mn
Mar 31, 2024 -131.00 Mn